Restylane® Defyne is a hyaluronic acid-based dermal filler developed for selected facial wrinkles, folds, and chin augmentation.
Part of Galderma’s Restylane family, Restylane Defyne is manufactured using XpresHAn Technology™, a hyaluronic acid gel technology designed to provide flexibility and support in areas where facial movement is an important consideration.
For aesthetic professionals, appropriate use of Restylane Defyne begins with understanding its intended applications, product characteristics, patient selection requirements, and the anatomical and safety considerations associated with dermal filler treatment.
What Is Restylane Defyne?
Restylane Defyne is a sterile, biodegradable, cross-linked hyaluronic acid injectable gel containing lidocaine.
Hyaluronic acid is naturally present in human tissues and plays an important role in hydration and extracellular matrix function. In dermal fillers, cross-linked HA creates a gel that can provide temporary structural correction or volume in selected treatment areas.
Restylane Defyne contains 20 mg/mL sodium hyaluronate and 3 mg/mL lidocaine hydrochloride according to current U.S. product information.
Its physical characteristics place it within the Restylane XpresHAn Technology family, which also includes products such as Restylane Refyne, Restylane Kysse, and Restylane Contour.
What Is XpresHAn Technology?
XpresHAn Technology™ is Galderma’s manufacturing technology used to create a family of flexible hyaluronic acid gels.
The technology is designed to balance flexibility and support so that treated tissues can continue moving with facial expression.
This characteristic is particularly relevant in dynamic areas of the face, where smiling, speaking, and other movements continuously change the shape of the surrounding soft tissue.
Rather than considering flexibility as an indication by itself, however, practitioners should still use each Restylane product according to its specific product information.
Products within the same technology family are not automatically interchangeable. Their individual characteristics and authorized treatment areas differ.
Current Restylane Defyne Indications
In the current U.S. Instructions for Use, Restylane Defyne is indicated for patients over 21 for two principal applications:
- Moderate to severe deep facial wrinkles and folds: Restylane Defyne is indicated for injection into the mid-to-deep dermis for correction of deep facial wrinkles and folds such as nasolabial folds.
- Chin augmentation: Restylane Defyne is indicated for injection into the mid-to-deep dermis, subcutaneous tissue, and/or supraperiosteal plane for augmentation of the chin region to improve the chin profile in patients with mild to moderate chin retrusion.
Practitioners should review the current instructions supplied for the product in their jurisdiction because indications and labeling may differ between markets.
Restylane Defyne for Nasolabial Folds
Nasolabial folds extend from the sides of the nose toward the corners of the mouth.
Their appearance is influenced by multiple factors, including facial anatomy, soft-tissue changes, facial movement, and aging.
Restylane Defyne is specifically indicated for moderate to severe deep facial wrinkles and folds such as nasolabial folds.
The product’s XpresHAn Technology is designed to provide flexible support in areas affected by facial movement.
This can be particularly relevant around the lower face, where treatment must be considered not only while the patient is at rest but also during smiling and speaking.
Assess More Than the Fold Itself
A visible nasolabial fold does not necessarily mean the fold should simply be filled until it disappears.
Practitioners should assess:
- Facial proportions
- Depth and symmetry of the folds
- Soft-tissue distribution
- Skin quality
- Previous filler treatment
- Facial movement
- The patient’s desired degree of correction
Overcorrection can alter facial proportions and produce an unnatural result.
The objective should therefore be appropriate improvement rather than elimination of every visible line.
Restylane Defyne for Chin Augmentation
Restylane Defyne is also specifically indicated for augmentation of the chin region in adults with mild to moderate chin retrusion.
Chin projection has an important influence on overall facial balance and profile.
During assessment, practitioners may consider:
- Chin projection
- Facial profile
- Lower-face proportions
- Chin width and shape
- Jaw and dental relationships
- Soft-tissue thickness
- Facial symmetry
- Patient goals
Treatment should be based on the patient’s anatomy rather than an arbitrary volume target.
Restylane Defyne’s current U.S. labeling allows placement for chin augmentation within specified tissue planes extending from the mid-to-deep dermis through subcutaneous and/or supraperiosteal implantation, depending on treatment needs.
Practitioners should follow the current Instructions for Use for product-specific injection guidance.
How Long Can Restylane Defyne Results Last?
Restylane Defyne is a temporary dermal filler.
Clinical data used in the product’s patient information demonstrate correction of nasolabial folds and improvement of chin profile that may persist for up to approximately 12 months in some patients.
Duration varies.
Factors that can influence treatment longevity include:
- Treatment area
- Individual anatomy
- Amount of product used
- Degree of correction
- Facial movement
- Individual biological response
- Previous and subsequent treatments
Practitioners should avoid guaranteeing a specific duration to an individual patient.
Patient Assessment Before Restylane Defyne Treatment
A detailed medical and aesthetic consultation should precede filler treatment.
The assessment should identify whether Restylane Defyne is appropriate for the patient’s concern and whether factors are present that may increase treatment risk.
Relevant considerations include:
- Aesthetic goals and expectations
- Previous dermal filler or injectable treatments
- Previous facial surgery or procedures
- History of severe allergies or anaphylaxis
- Allergy to lidocaine or related local anesthetics
- Relevant medication use
- Bleeding disorders or tendency to bruise
- Active inflammatory skin conditions
- Active infection in or near the planned treatment area
- Previous adverse filler reactions
- Scar formation or healing concerns
Practitioners should also examine the patient’s facial anatomy both at rest and during animation.
Standardized pretreatment photography can assist with documentation and subsequent evaluation of results.
Contraindications and Precautions
Current U.S. product information lists contraindications that include severe allergies manifested by a history of anaphylaxis or multiple severe allergies, allergy to gram-positive bacterial proteins that may be present in trace amounts, and allergy to lidocaine or other amide-type local anesthetics.
Treatment should also be deferred at sites where active inflammation or infection is present until the underlying condition has been controlled.
Practitioners should consult the complete current Instructions for Use rather than relying on a simplified contraindication list because additional warnings and precautions may affect individual treatment decisions.
Understanding Vascular Risk
The most serious risks associated with facial dermal filler treatment are related to inadvertent injection into, obstruction of, or compromise of blood vessels.
Restylane Defyne should not be implanted into blood vessels.
Intravascular filler placement can result in vascular occlusion and tissue ischemia.
Rare but serious complications reported with facial soft-tissue fillers include:
- Skin necrosis
- Temporary or permanent visual impairment
- Blindness
- Cerebral ischemia
- Stroke
- Damage to underlying facial structures
Practitioners should have appropriate training and detailed knowledge of vascular anatomy in and around the treatment area.
The current Restylane Defyne Instructions for Use also advise careful injection technique, including slow injection and use of the least amount of pressure necessary.
Recognizing Possible Vascular Compromise
Early recognition of vascular complications is essential.
Warning signs during or shortly after treatment can include:
- Unusual or disproportionate pain
- Blanching or unusual skin-color changes
- Changes in vision
- Neurological symptoms or signs of stroke
If symptoms suggesting intravascular injection occur, injection should be stopped immediately and the patient should receive prompt medical assessment according to established emergency and complication-management protocols.
Patients should also receive clear instructions about symptoms that require urgent contact after leaving the clinic.
Common Treatment-Site Reactions
Temporary local reactions are common following dermal filler treatment.
Clinical studies of Restylane Defyne have reported effects such as:
- Swelling
- Redness
- Bruising
- Pain or tenderness
- Lumps or bumps
- Itching
These reactions vary in severity and duration.
Delayed inflammatory reactions, nodules, infection, and other adverse events have also been reported with HA fillers.
Patients should understand the difference between expected post-injection effects and symptoms that require clinical evaluation.
Natural-Looking Results and Facial Movement
One of the features associated with Restylane’s XpresHAn Technology is its ability to provide flexible support while accommodating facial expression.
This makes facial animation an important part of both assessment and evaluation.
A treatment may look balanced while the patient is resting yet behave differently when the patient smiles or speaks.
Practitioners can therefore evaluate:
- Appearance at rest
- Smile dynamics
- Lower-face movement
- Chin movement
- Symmetry during expression
Natural-looking outcomes generally depend on the interaction of product choice, anatomy, placement, treatment amount, and patient expectations rather than any single injection technique.
A Conservative, Individualized Treatment Strategy
Dermal filler treatment should not be approached as a standardized volume prescription.
Two patients with apparently similar nasolabial folds or chin profiles may require different treatment strategies because of anatomical differences.
Individual planning should consider:
- What anatomical feature is actually producing the concern
- Whether filler is the appropriate treatment modality
- How much correction is appropriate
- Where product support is needed
- How treatment will affect overall facial proportions
A conservative approach can also make it easier to assess the patient’s response before deciding whether additional correction is appropriate.
Restylane Defyne Versus Other Restylane Products
The Restylane family contains multiple HA fillers designed for different aesthetic applications.
For example, products within the portfolio are available for concerns involving lips, cheeks, temples, infraorbital hollowing, facial wrinkles, folds, hands, and chin augmentation depending on the specific product.
Restylane Defyne should therefore not automatically be selected simply because the patient requests a Restylane filler.
The treatment objective should determine product selection.
Other Restylane products may be more appropriate when the desired treatment area or indication falls outside Defyne’s established uses.
Can Restylane Defyne Be Used for the Midface, Temples, or Jawline?
Practitioners should distinguish between a product’s documented indication and broader discussions of off-label clinical practice.
Current U.S. Restylane Defyne labeling specifically establishes safety and effectiveness for deep facial wrinkles and folds such as nasolabial folds and for chin augmentation in mild to moderate chin retrusion.
The current Instructions for Use state that safety and effectiveness for uses other than treatment of the chin and nasolabial folds have not been established in controlled clinical studies.
Other products in the Restylane portfolio carry specific indications for areas such as the cheeks, temples, lips, and infraorbital hollowing.
Product selection should therefore be guided by the current labeling, patient anatomy, practitioner qualifications, and applicable local requirements.
Restylane Defyne and Combination Treatment Planning
Dermal fillers are frequently one component of a broader aesthetic treatment strategy.
Different procedures address different aspects of facial aging.
For example:
- Botulinum toxin type A can address selected concerns related to muscle activity.
- Dermal fillers can address selected folds, volume deficits, and structural concerns.
- Laser and energy-based procedures may address certain aspects of skin texture and photodamage.
- Chemical peels and other resurfacing treatments may address selected superficial skin concerns.
Combination treatment does not necessarily mean performing all procedures during the same session.
The timing and sequence of treatments should account for product information, tissue healing, the treatment area, patient factors, and potential inflammatory effects.
Restylane Defyne labeling specifically advises practitioners to consider planned cosmetic treatments such as laser procedures or chemical peels because an inflammatory reaction at the implant site may occur.
Training and Clinical Preparation
Restylane Defyne should be used by appropriately trained healthcare practitioners with knowledge of anatomy in and around the injection site.
Training should extend beyond learning individual injection patterns.
Important areas of competency include:
- Facial anatomy
- Vascular anatomy
- Patient selection
- Product characteristics
- Aseptic technique
- Recognition of adverse events
- Management of filler complications
- Informed consent
- Emergency escalation procedures
Practitioners should maintain current product information and complication-management protocols within the practice.
Documenting Restylane Defyne Treatment
Good documentation supports continuity of care and product traceability.
A treatment record may include:
- Product name
- Lot or traceability information
- Treatment area
- Relevant treatment details
- Patient assessment
- Informed consent
- Before-and-after photographs
- Immediate patient response
- Follow-up findings
- Any adverse events and their management
Practices should follow applicable requirements for medical documentation and injectable product traceability.
Post-Treatment Follow-Up
Follow-up gives the practitioner an opportunity to evaluate the aesthetic result, tissue response, symmetry, and patient satisfaction.
It can also help identify delayed concerns.
Patients should receive instructions explaining expected post-treatment reactions, how to contact the practice, and which symptoms require urgent evaluation.
Rather than providing every patient with generic filler advice, aftercare instructions should reflect the specific product, treatment area, procedure performed, and current manufacturer recommendations.
Conclusion
Restylane Defyne is a cross-linked hyaluronic acid dermal filler developed with XpresHAn Technology to provide flexible support in selected dynamic areas of the face.
Its established applications include correction of moderate to severe deep facial wrinkles and folds such as nasolabial folds and augmentation of the chin in adults with mild to moderate chin retrusion.
For practitioners, effective treatment depends on more than the characteristics of the filler itself.
Patient selection, facial and vascular anatomy, appropriate product choice, conservative treatment planning, complication preparedness, informed consent, and careful follow-up all contribute to responsible dermal filler practice.
Licensed medical practitioners can buy Restylane Defyne at Health Supplies Plus.
Restylane Defyne Frequently Asked Questions
Restylane Defyne is a cross-linked hyaluronic acid dermal filler containing lidocaine. It is manufactured using Galderma’s XpresHAn Technology and is designed for selected facial wrinkles, folds, and chin augmentation applications.
Current U.S. labeling indicates Restylane Defyne for correction of moderate to severe deep facial wrinkles and folds such as nasolabial folds and for chin augmentation to improve the chin profile in adults with mild to moderate chin retrusion. Indications may vary by jurisdiction.
XpresHAn Technology is Galderma’s HA gel technology designed to provide flexible support and accommodate natural facial movement. Several products within the Restylane portfolio use the technology, but each product has its own characteristics and indications.
Yes. Correction of moderate to severe deep facial wrinkles and folds such as nasolabial folds is an established indication for Restylane Defyne in adults over 21 under current U.S. labeling.
Yes. Current U.S. labeling includes augmentation of the chin region to improve chin profile in adults with mild to moderate chin retrusion.
Clinical information shows that results for treated nasolabial folds and chin augmentation may persist for up to approximately 12 months in some patients. Individual duration varies and should not be guaranteed.
Restylane Defyne uses XpresHAn Technology, which is designed to provide flexible support and accommodate facial expression. Natural-looking outcomes also depend on anatomy, product placement, treatment amount, and practitioner technique.
Restylane Defyne should be selected according to an appropriate aesthetic indication and individual patient assessment rather than age alone. Current product labeling does not establish a general indication for preventing future wrinkles or preserving skin elasticity.
Current U.S. labeling establishes Restylane Defyne for selected deep facial wrinkles and folds and chin augmentation. Its Instructions for Use state that safety and effectiveness for treatment areas other than the chin and nasolabial folds have not been established in controlled clinical studies. Other Restylane products carry specific midface indications.
Jawline and temple treatment should not be presented as established Restylane Defyne indications based on current U.S. labeling. Practitioners should select products according to the specific indication, current labeling, anatomy, and applicable local requirements.
Reported treatment-site reactions include swelling, redness, bruising, pain or tenderness, itching, and lumps or bumps. Severity and duration vary between patients.
Rare but serious complications can occur if filler enters or compromises a blood vessel. These may include tissue ischemia and necrosis, visual impairment or blindness, and neurological complications such as stroke.
The product should be used by appropriately qualified healthcare practitioners with relevant training, experience, and detailed knowledge of anatomy around the intended injection site.
Restylane Defyne is a hyaluronic acid-based filler. Hyaluronidase may be used by appropriately trained practitioners in the management of selected HA filler corrections or complications. Its use should follow an established clinical protocol rather than being viewed as a risk-free universal reversal procedure.
Restylane Defyne may form part of a broader individualized treatment plan, but procedure selection, timing, and sequencing should be assessed carefully. Current product information advises caution when other cosmetic procedures such as laser treatments or chemical peels are planned because inflammation at the implant site may occur.
Assessment may include fold depth, facial proportions, symmetry, soft-tissue distribution, skin quality, previous filler treatment, facial animation, medical history, and the patient’s desired degree of correction.
Chin projection, facial profile, lower-face proportions, width, symmetry, soft-tissue thickness, dental and skeletal relationships, previous procedures, and patient goals should all be considered during treatment planning.
No. Wrinkles can result from muscle activity, skin changes, volume loss, structural anatomy, or combinations of these factors. Patient assessment should determine whether filler and the specific Restylane Defyne indication are appropriate for the concern being treated.
Facial blood vessels can be injured, compressed, or inadvertently injected during filler treatment. Detailed knowledge of anatomy is essential for reducing risk and recognizing potential vascular complications quickly.
Licensed medical practitioners can purchase Restylane Defyne from Health Supplies Plus, subject to applicable professional and local requirements.
About the Author: Doris Dickson is a specialist writer for Health Supplies Plus, focusing on the aesthetic medicine industry. She diligently researches cosmetic treatments and products to provide clear, concise information relevant to licensed medical professionals. Her work supports Health Supplies Plus’s commitment to being a reliable informational resource and trusted supplier for the aesthetic community.
Disclaimer: The content provided in this article is intended for informational purposes only and is directed towards licensed medical professionals. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment, nor does it constitute an endorsement of any specific product or technique. Practitioners must rely on their own professional judgment, clinical experience, and knowledge of patient needs, and should always consult the full product prescribing information and relevant clinical guidelines before use. Health Supplies Plus does not provide medical advice.